

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0104				
Estimated averag	e burden				
nours per respons	se 0.5				

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Statem	ent (Month/Da	_	3. Issuer Name and Ticker or Trading Symbol Aurinia Pharmaceuticals Inc. [AUPH]				
01/01	/2021		Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)	
			Director X Officer (give tit below)	le 10% Ówner Other (speci	fy Applicab _X_Form	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person	
		Table I -	- Non-Derivat	ive Securities	Beneficially	Owned	
1.Title of Security (Instr. 4)			Beneficially Owned For (D) (I)		. Nature of Indirect Beneficial Ownership Instr. 5)		
spond to the displays a c	collection of urrently valid	f information I OMB contr	n contained in to		·		
		d 3. Title and Amount of		4. Conversion	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
Date Exercisable	Expiration Date	Title	Amount or Number of Shar	Security	Direct (D) or Indirect (I) (Instr. 5)	r	
(1)	08/19/2029	Common	250,000	\$ 5.9 (2)	D		
		Stock		Ψ 0.,			
(3)	01/28/2030	Common	126,500	\$ 18.38 (2)	D		
	class of securities spond to the displays a covative Securities Expiration I (Month/Day/Ye) Date Exercisable	Statement (Month/Da) 01/01/2021 2. A Ben (Ins) class of securities beneficially spond to the collection of displays a currently valid 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date	Statement (Month/Day/Year) 01/01/2021 Table I 2. Amount of Sec Beneficially Own (Instr. 4) Class of securities beneficially owned direct spond to the collection of information displays a currently valid OMB contravative Securities Beneficially Owned (e.g. 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date Exercisable Date Title (1) 08/19/2029 Common	Statement (Month/Day/Year) 01/01/2021 4. Relationship of Issuer (Check Director X Officer (give tit below) Ex VP, Ir Table I - Non-Derivat 2. Amount of Securities Beneficially Owned (Instr. 4) Class of securities beneficially owned directly or indirectly. spond to the collection of information contained in the displays a currently valid OMB control number. vative Securities Beneficially Owned (e.g., puts, calls, warred) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivation Security (Instr. 4) Date Expiration Date (Month/Day/Year) Common 250 000	Statement (Month/Day/Year) 01/01/2021 Aurinia Pharmaceuticals Inc. 4. Relationship of Reporting Person(Issuer (Check all applicable) Director X_Officer (give title below) Ex VP, Intern'l Operations Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 5) Class of securities beneficially owned directly or indirectly. Spond to the collection of information contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number. Vative Securities Beneficially Owned (e.g., puts, calls, warrants, options, contained in this form are not displays a currently valid OMB control number.	Statement (Month/Day/Year) O1/01/2021	

Reporting Owners

	Relationships			
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Donley Matthew Maxwell #1203-4464 MARKHAM STREET VICTORIA, A1 V8Z7X8			Ex VP, Intern'l Operations	

Signatures

/s/ Stephen Robertson, Attorney-in-Fact for Matthew Maxwell Donley	01/04/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter
- (2) Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
- (3) The shares subject to the option vest in thirty-six equal monthly installments from the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of JOSEPH MILLER, STEPHEN ROBERTSON, JOHN MCKENNA and ROSE MCKINLEY, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of AURINIA PHARMACEUTICALS INC. (the "Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 or Form ID (including any amendments thereto) and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of December 18, 2020.

/s/ Matthew Maxwell Donley Matthew Maxwell Donley